HIV Infections Clinical Trial
Official title:
Evaluate Tolerability and Safety of Multi-Envelope, Prime-boost HIV Vaccine (DVP) in Healthy Adults
Vaccines have been very successful in preventing viral infections such as hepatitis B and
the measles. Viral vaccines work by causing a person's immune system to make cells that will
work against the virus. Due to the success in treating other viral infections, scientists
are trying to develop a vaccine for human immunodeficiency virus (HIV). HIV infection is the
cause of acquired immune deficiency syndrome (AIDS). AIDS is one of the most serious viral
infections we know.
This is a research study to evaluate the safety of a possible vaccine against HIV.
Researchers want to determine that a person's immune system can respond to the HIV before he
or she is exposed to it. Therefore that person may be able to be protected from infection
with HIV.
This is a research study to find out about the safety of a new potential vaccine regimen
against HIV. This potential vaccine regimen consists of a sequence of six vaccine shots that
are being studied to see if they can help to protect people from the human immunodeficiency
virus (HIV). HIV infection is the cause of AIDS. AIDS is one of the most serious viral
infections we know. Twenty million people around the world have already died of AIDS and
over 40 million people are currently infected with the virus. This study is being done to
help us find an HIV vaccine that works.
Vaccines have been very successful in preventing other viral infections, such as hepatitis
B, polio, and measles. Viral vaccines work by causing a person's immune system to make
antibodies and immune cells against the virus or to "respond" to the virus. Because of the
success with other viral infections, scientists are trying to develop a successful vaccine
for HIV. If a person's immune system can respond to HIV before he or she is exposed to it,
that person may be able to be protected from infection with HIV.
The vaccine regimen that will be tested in this study is based on the information that the
virus uses to make a small part of the HIV. This small part is called the "envelope" or
coating around the virus. Because only the information for this one part of the virus is
used in the vaccine, the vaccine cannot cause HIV infection. We make all parts of the
vaccine regimen in test tubes.
;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT05454514 -
Automated Medication Platform With Video Observation and Facial Recognition to Improve Adherence to Antiretroviral Therapy in Patients With HIV/AIDS
|
N/A | |
| Completed |
NCT03760458 -
The Pharmacokinetics, Safety, and Tolerability of Abacavir/Dolutegravir/Lamivudine Dispersible and Immediate Release Tablets in HIV-1-Infected Children Less Than 12 Years of Age
|
Phase 1/Phase 2 | |
| Completed |
NCT03141918 -
Effect of Supplementation of Bioactive Compounds on the Energy Metabolism of People Living With HIV / AIDS
|
N/A | |
| Completed |
NCT03067285 -
A Phase IV, Open-label, Randomised, Pilot Clinical Trial Designed to Evaluate the Potential Neurotoxicity of Dolutegravir/Lamivudine/Abacavir in Neurosymptomatic HIV Patients and Its Reversibility After Switching to Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide. DREAM Study
|
Phase 4 | |
| Recruiting |
NCT04579146 -
Coronary Artery Disease (CAD) in Patients HIV-infected
|
||
| Completed |
NCT06212531 -
Papuan Indigenous Model of Male Circumcision
|
N/A | |
| Active, not recruiting |
NCT03256422 -
Antiretroviral Treatment Taken 4 Days Per Week Versus Continuous Therapy 7/7 Days Per Week in HIV-1 Infected Patients
|
Phase 3 | |
| Completed |
NCT03256435 -
Retention in PrEP Care for African American MSM in Mississippi
|
N/A | |
| Completed |
NCT00517803 -
Micronutrient Supplemented Probiotic Yogurt for HIV/AIDS and Other Immunodeficiencies
|
N/A | |
| Active, not recruiting |
NCT03572335 -
Systems Biology of Diffusion Impairment in Human Immunodeficiency Virus (HIV)
|
||
| Completed |
NCT04165200 -
Fecal Microbiota Transplantation as a Therapeutic Strategy for Patients Infected With HIV
|
N/A | |
| Recruiting |
NCT03854630 -
Hepatitis B Virus Vaccination in HIV-positive Patients and Individuals at High Risk for HIV Infection
|
Phase 4 | |
| Terminated |
NCT03275571 -
HIV, Computerized Depression Therapy & Cognition
|
N/A | |
| Completed |
NCT02234882 -
Study on Pharmacokinetics
|
Phase 1 | |
| Completed |
NCT01618305 -
Evaluating the Response to Two Antiretroviral Medication Regimens in HIV-Infected Pregnant Women, Who Begin Antiretroviral Therapy Between 20 and 36 Weeks of Pregnancy, for the Prevention of Mother-to-Child Transmission
|
Phase 4 | |
| Recruiting |
NCT05043129 -
Safety and Immune Response of COVID-19 Vaccination in Patients With HIV Infection
|
||
| Not yet recruiting |
NCT05536466 -
The Influence of Having Bariatric Surgery on the Pharmacokinetics, Safety and Efficacy of the Novel Non-nucleoside Reverse Transcriptase Inhibitor Doravirine
|
N/A | |
| Recruiting |
NCT04985760 -
Evaluation of Trimer 4571 Therapeutic Vaccination in Adults Living With HIV on Suppressive Antiretroviral Therapy
|
Phase 1 | |
| Completed |
NCT05916989 -
Stimulant Use and Methylation in HIV
|
||
| Terminated |
NCT02116660 -
Evaluation of Renal Function, Efficacy, and Safety When Switching From Tenofovir/Emtricitabine Plus a Protease Inhibitor/Ritonavir, to a Combination of Raltegravir (MK-0518) Plus Nevirapine Plus Lamivudine in HIV-1 Participants With Suppressed Viremia and Impaired Renal Function (MK-0518-284)
|
Phase 2 |